UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2015

Commission File Number: 001-34541

CHINA CORD BLOOD CORPORATION

(Translation of registrant’s name into English)

48th Floor, Bank of China Tower

1 Garden Road

Central

Hong Kong S.A.R.

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .

EXPLANATORY NOTE

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or China Cord Blood Corporation’s (the “Company”) future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Report on Form 6-K is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company’s expectations are as of the date of this Report on Form 6-K, and the Company does not intend to update any of the forward-looking statements after the date of this Report on Form 6-K to conform these statements to actual results, unless required by law.

The forward-looking statements included in this Report on Form 6-K are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments (including revisions to China’s One Child Policy) in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in the PRC, as well as general economic conditions; compliance with restrictive debt covenants under the Company’s senior convertible notes; the non-binding proposal letter from Golden Meditech Holdings Limited; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission in the United States.

Results of Operations and Financial Condition

Following this cover page are the preliminary unaudited condensed consolidated financial results for the three months and year ended March 31, 2015 of the Company.

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31, 2014 and 2015

	March 31,		March 31,
	2014		2015
	RMB		RMB		US$
	(in thousands except share data)
ASSETS
Current assets
Cash and cash equivalents	1,882,901		2,436,655		393,072
Trading securities	—		7,708		1,243
Accounts receivable, less allowance for doubtful accounts (March 31, 2014: RMB20,322; March 31, 2015: RMB28,624 (US$4,618))	95,273		120,762		19,480
Inventories	31,583		23,803		3,840
Prepaid expenses and other receivables	37,010		19,508		3,147
Debt issuance costs	3,616		3,592		579
Deferred tax assets	7,664		10,270		1,657
Total current assets	2,058,047		2,622,298		423,018
Property, plant and equipment, net	626,632		603,167		97,301
Non-current prepayments	208,894		207,258		33,434
Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2014: RMB42,703; March 31, 2015: RMB55,211 (US$8,906))	225,496		194,238		31,334
Inventories	48,385		58,224		9,392
Intangible assets, net	120,549		115,928		18,701
Available-for-sale equity securities	144,247		122,416		19,748
Other investment	189,129		189,129		30,510
Debt issuance costs	7,854		4,210		679
Deferred tax assets	1,789		2,618		422
Total assets	3,631,022		4,119,486		664,539

LIABILITIES
Current liabilities
Bank loan	60,000		60,000		9,679
Accounts payable	10,422		12,673		2,044
Accrued expenses and other payables	102,559		87,381		14,097
Deferred revenue	196,432		220,140		35,512
Amounts due to related parties	21,453		20,802		3,355
Income tax payable	2,571		10,081		1,626
Deferred tax liabilities	3,900		9,100		1,468
Total current liabilities	397,337		420,177		67,781
Convertible notes	777,753		815,851		131,610
Non-current deferred revenue	823,921		1,099,399		177,351
Other non-current liabilities	164,077		215,585		34,777
Deferred tax liabilities	27,938		25,261		4,075
Total liabilities	2,191,026		2,576,273		415,594

EQUITY
Shareholders’ equity of China Cord Blood Corporation
Ordinary shares
- US$0.0001 par value, 250,000,000 shares authorized, 73,140,147 shares issued and 73,003,248 shares outstanding as of March 31, 2014 and 2015, respectively	50		50		8
Additional paid-in capital	798,221		814,678		131,420
Treasury stock, at cost (March 31, 2014 and 2015: 136,899 shares, respectively)	(2,815	)	(2,815	)	(454	)
Accumulated other comprehensive income	84,263		63,230		10,200
Retained earnings	555,323		662,615		106,891
Total equity attributable to China Cord Blood Corporation	1,435,042		1,537,758		248,065
Non-controlling interests	4,954		5,455		880
Total equity	1,439,996		1,543,213		248,945
Total liabilities and equity	3,631,022		4,119,486		664,539

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months and Year ended March 31, 2014 and 2015

	Three months ended March 31,						Year ended March 31,
	2014		2015				2014		2015
	RMB		RMB		US$		RMB		RMB		US$
	(in thousands except per share data)

Revenues	151,915		162,994		26,294		572,857		635,122		102,456
Direct costs	(27,341	)	(34,440	)	(5,556	)	(106,225	)	(130,611	)	(21,070	)
Gross profit	124,574		128,554		20,738		466,632		504,511		81,386
Operating expenses
Research and development	(2,539	)	(2,660	)	(429	)	(9,773	)	(9,907	)	(1,598	)
Sales and marketing	(28,415	)	(34,960	)	(5,640	)	(112,689	)	(127,927	)	(20,637	)
General and administrative	(29,607	)	(41,411	)	(6,680	)	(112,244	)	(131,681	)	(21,242	)
Total operating expenses	(60,561	)	(79,031	)	(12,749	)	(234,706	)	(269,515	)	(43,477	)
Operating income	64,013		49,523		7,989		231,926		234,996		37,909
Other expense, net
Interest income	4,615		4,708		759		16,870		18,252		2,944
Interest expense	(16,990	)	(25,238	)	(4,071	)	(70,075	)	(101,102	)	(16,309	)
Exchange gain/(loss)	329		(82	)	(13	)	80		(231	)	(37	)
Dividend income	—		—		—		9,911		2,344		378
Others	565		101		16		2,212		861		139
Total other expense, net	(11,481	)	(20,511	)	(3,309	)	(41,002	)	(79,876	)	(12,885	)
Income before income tax	52,532		29,012		4,680		190,924		155,120		25,024
Income tax expense	(12,830	)	(11,664	)	(1,882	)	(58,398	)	(47,327	)	(7,635	)
Net income	39,702		17,348		2,798		132,526		107,793		17,389
Net income attributable to non-controlling interests	(163	)	(425	)	(69	)	(623	)	(501	)	(81	)
Net income attributable to China Cord Blood Corporation’s shareholders	39,539		16,923		2,729		131,903		107,292		17,308

Net income per share:
Attributable to ordinary shares
- Basic	0.46		0.23		0.04		1.60		1.36		0.22
- Diluted	0.46		0.23		0.04		1.60		1.36		0.22

Other comprehensive income
- Net effect of foreign currency translation, net of nil tax	(3,686	)	1,360		219		8,299		4,642		749
- Net unrealized (loss)/gain in available-for-sale equity securities, net of nil tax	(6,346	)	12,934		2,086		57,708		(25,675	)	(4,142	)
Comprehensive income	29,670		31,642		5,103		198,533		86,760		13,996

Comprehensive income attributable to non-controlling interests	(163	)	(425	)	(69	)	(623	)	(501	)	(81	)
Comprehensive income attributable to China Cord Blood Corporation’s shareholders	29,507		31,217		5,034		197,910		86,259		13,915

Other Events

On June 18, 2015, the Company issued a press release announcing preliminary unaudited condensed consolidated financial results for the three months and year ended March 31, 2015. A copy of the press release is attached as Exhibit 99.1.

Exhibits

Exhibit No.		Description

99.1		Press Release, dated June 18, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CHINA CORD BLOOD CORPORATION

	By:	/s/ Albert Chen
	Name:	Albert Chen
	Title:	Chief Financial Officer

Dated: June 18, 2015